Looking for high-quality L-lysine(Trifluoroacetic Acid)-NCA? Look no further! We are a reputable factory offering top-notch products. Contact us today!
Transportation condition&recommended shipping method: by air, by sea or by express Storage condition: Inert atmosphere,Store in freezer, under -20°C Minimum Order Qty: Negotiation Certification: COA, HPLC, GC, HNMR, Assay, Water Content(K.F), TLC availableN-[4-[(4S)-2,5-dioxooxazolidin-4-yl]butyl]-2,2,2-trifluoro-acetamide; e-Trifluoroacetyl-Lysine, NCA; N-Trifluoroacetyl-L-lysine N-carboxyanhydride; N-(4-(2,5-Dioxo-4-oxazolidinyl)butyl)-2,2,2-trifluoroacetamide; N6-Trifluoroacetyl-L-lysine N-Carboxyanhydride; L-Lysine-N-Trifluoroacetyl-N-Carboxyanhydride; (S)-N-[4-(2,5-Dioxo-4-oxazolidinyl)butyl]-2,2,2-trifluoroacetaMide; N-[4-[(4S)-2,5-Dioxo-4-oxazolidinyl]butyl]-2,2,2-trifluoroacetaMide;They are usually used to pack powder. And they can prevent sunshine and water from getting bad.The hard carton can protect your products from crashing and getting wet.Used in the synthesis ofnew arborescent architectures ofpoly(L-lysine),called lysine dendrigraft(DGL)polymers. DGL polymers were prepd.Through a multiple-generation scheme (up to generation 5) in a weakly acidic aq. Medium by polycondensing N.vepsiln.-trifluoroacetyl-L-lysine-N-carboxyanhydride (Lys(Tfa)-NCA) onto the previous generation G(n-1) of DGL, which was used as a macroinitiator. Glatil injection is the world's best-selling multiple sclerosis drug. However, as the patent for the generic Copaxone expires, the drug will gradually be hit by cheaper generics. In April 2015, Sandoz, a generic drug subsidiary of Novartis, successfully developed a generic drug Glatopa and obtained FDA approval. The drug is a generic version of Teva's brand name Copaxone. Glatopa is also the first generic version of Copaxone approved by the FDA as a once-daily injectable drug for the treatment of relapsing multiple sclerosis. Glatopa, developed in the United States by Novassandoz in collaboration with Momenta, is indicated for the treatment of patients with relapsing multiple sclerosis (RMM), as well as patients who have experienced a first clinical episode and whose magnetic resonance imaging (MRI) features are consistent with MS. As a complex compound that is difficult to generalize, the FDA has received DMF approval from four API manufacturers: Dr Reddys Laboratories Ltd. (India), Ambiopharm Inc. (USA), and Peptisyntha Sa (Belgium). And China Hanyu Pharmaceutical. More companies will compete in the multiple sclerosis drug market as patents expire. Glatiramer acetate is a synthetic analogue of myelin basic proteins and an immunomodulator that can be used in multiple sclerosis studies. Glatiramer acetate showed strong and haptic binding to MHC molecules and thus competed with various myelin antigens for presentation to T cells. Another aspect of Glatiramer acetate's effect was to effectively induce T-helper cell 2 (Th2) specific inhibitory cell migration to the brain and result in in situ bystander inhibition.
L-Lys(Boc)
Boc-Lys(Cbz)-Ol
Z-Lys(boc)-Ala-Ala-OBzl
Fmoc-L-Lys(Fmoc)-OH
Lys(Fmoc)-OH
Boc-Lys(AC)
L-Lys-oet.2HCl
Fmoc-D-Lys(Boc)-OH
L-Lys(Cbz)-OH
Boc-L-Lys(Cbz)-OH
D-Lys-Ome.2Hcl
Fmoc-L-Lys(Boc)-OH
D-Lys(cbz)-OH
Boc-L-Lys(Boc)-OSu
H-L-Lys(cbz)-OBzl•HCl
Fmoc-L-Lys-OH·HCl
H-Lys(Ac)-OH
Boc-L-Lys(Boc)-OH·DCHA
L-Lys(cbz)-Ome.Hcl
Fmoc-Lys-Ome·HCl
Lys(tfa)-OH
Boc-D-Lys(Boc)-OH
lys(Cbz)-Otbu.HCl
Fmoc-D-Lys-OH·HCl
D-Lys(tfa)-OH
Boc-L-Lys(Cbz)-OMe
D-Lys(Cbz)-OtBu.HCl
Cbz-Lys(tfa)-OH
D-Lys（tfa）-NCA
Boc-D-Lys(Cbz)-OH
L-Lys.2Hcl
Cbz-lys（cbz）-osu
L-Lys(tfa)-NCA
Boc-L-Lys(Cbz)-OH·DCHA
L-Lys-Ome.2Hcl
Cbz-L-Lys(Cbz).DCHA
Lys(Cbz)-NCA
Boc-L-Lys(Fmoc)-OH
H-Lys-Lys.3HCl
Cbz-L-Lys-OH
D-Lys(Cbz)-NCA
Fmoc-L-Lys(tfa)-OH
lys-obzl.2hcl
Cbz-L-Lys(Cbz)-OH
Z-L-Lys(Boc).DCHA
Fmoc-L-Lys(DDC)
D-Lys(Fmoc).HCl
Cbz-Lys(AC)-OH
Ac-Lys-OH
Fmoc-D-Lys(Cbz)-OH
Lys(Fmoc).HCl
Cbz-Lys(BOC)-ome
AC-Lys(Boc)-NH2
Fmoc-D-Lys(Fmoc)-OH
D-Lys.Hcl
Cbz-Lys(Boc)-Otbu
AC-Lys(Boc)-OH
Fmoc-L-Lys(Cbz)
D,L-Lys.Hcl
Cbz-L-Lys(BOC)-OH
H-Lys(Cbz)-OtBu
Fmoc-L-Lys(AC)
L-Lys.HCl
Cbz-L-Lys(Fmoc)-OH
Boc-Lys（Cbz）.DCHA
Cbz-L-Lys-Ome.Hcl
Boc-L-Lys-OH
Cbz-L-Lys-obzl.Hcl
Boc-Lys(tfa)-OH
Z-DL-Lys(cbz)-OH
1. R&D service available 2. ISO certified manufacturer, quality guarantee 3.A full course of follow-up service during production 4.High cost effective 5.Quality certification documents provided per customer's request 6.Great after-sales service, maintaining close relationship with customer 7.Full resource to help decrease shipping costs 8.Free sample offered to check out quality prior to any payment 9.Payment term negotiated 10.Assit customers deal with affairs in China
N-[4-[(4S)-2,5-dioxooxazolidin-4-yl]butyl]-2,2,2-trifluoro-acetamide; e-Trifluoroacetyl-Lysine, NCA; N-Trifluoroacetyl-L-lysine N-carboxyanhydride; N-(4-(2,5-Dioxo-4-oxazolidinyl)butyl)-2,2,2-trifluoroacetamide; N6-Trifluoroacetyl-L-lysine N-Carboxyanhydride; L-Lysine-N-Trifluoroacetyl-N-Carboxyanhydride; (S)-N-[4-(2,5-Dioxo-4-oxazolidinyl)butyl]-2,2,2-trifluoroacetaMide; N-[4-[(4S)-2,5-Dioxo-4-oxazolidinyl]butyl]-2,2,2-trifluoroacetaMide;They are usually used to pack powder. And they can prevent sunshine and water from getting bad.
The hard carton can protect your products from crashing and getting wet.
Used in the synthesis ofnew arborescent architectures ofpoly(L-lysine),called lysine dendrigraft(DGL)polymers. DGL polymers were prepd.Through a multiple-generation scheme (up to generation 5) in a weakly acidic aq. Medium by polycondensing N.vepsiln.-trifluoroacetyl-L-lysine-N-carboxyanhydride (Lys(Tfa)-NCA) onto the previous generation G(n-1) of DGL, which was used as a macroinitiator. Glatil injection is the world's best-selling multiple sclerosis drug. However, as the patent for the generic Copaxone expires, the drug will gradually be hit by cheaper generics. In April 2015, Sandoz, a generic drug subsidiary of Novartis, successfully developed a generic drug Glatopa and obtained FDA approval. The drug is a generic version of Teva's brand name Copaxone. Glatopa is also the first generic version of Copaxone approved by the FDA as a once-daily injectable drug for the treatment of relapsing multiple sclerosis. Glatopa, developed in the United States by Novassandoz in collaboration with Momenta, is indicated for the treatment of patients with relapsing multiple sclerosis (RMM), as well as patients who have experienced a first clinical episode and whose magnetic resonance imaging (MRI) features are consistent with MS. As a complex compound that is difficult to generalize, the FDA has received DMF approval from four API manufacturers: Dr Reddys Laboratories Ltd. (India), Ambiopharm Inc. (USA), and Peptisyntha Sa (Belgium). And China Hanyu Pharmaceutical. More companies will compete in the multiple sclerosis drug market as patents expire. Glatiramer acetate is a synthetic analogue of myelin basic proteins and an immunomodulator that can be used in multiple sclerosis studies. Glatiramer acetate showed strong and haptic binding to MHC molecules and thus competed with various myelin antigens for presentation to T cells. Another aspect of Glatiramer acetate's effect was to effectively induce T-helper cell 2 (Th2) specific inhibitory cell migration to the brain and result in in situ bystander inhibition.
